Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sarcomas and pharmacogenetics.

Paola Biason1, Giuseppe Toffoli

  • 1CRO, National Cancer Institute, Experimental and Clinical Pharmacology, Via Pedemontana Occidentale, 12 33081 Aviano, PN, Italy.

Pharmacogenomics
|September 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

Nanomedicine (London, England)·2026
Same author

HLA-G alleles in Italian patients with locally advanced rectal cancer (LARC).

Human immunology·2026
Same author

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.

EClinicalMedicine·2026
Same author

Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer.

Cancers·2025
Same author

Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.

Oncogene·2025
Same author

Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.

Scientific reports·2025

Pharmacogenetics significantly impacts chemotherapy response and toxicity in various sarcoma subtypes. Identifying predictive genetic markers is crucial for tailoring treatments for soft tissue sarcomas (STS) and bone sarcomas.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Cancer Chemotherapy

Background:

  • Sarcomas are diverse tumors necessitating tailored chemotherapy.
  • Chemotherapy response varies among sarcoma histologic subtypes.
  • Pharmacogenetics plays a key role in predicting patient response and toxicity to chemotherapy drugs.

Purpose of the Study:

  • To evaluate the impact of pharmacogenetics on chemotherapy efficacy in different sarcoma subtypes.
  • To identify potential genetic markers influencing treatment outcomes for soft tissue sarcomas (STS) and bone sarcomas.
  • To explore the role of genetic polymorphisms in drug metabolism, transport, and target proteins in sarcoma treatment.

Main Methods:

  • Review of existing literature on pharmacogenetic studies in sarcoma chemotherapy.

Related Experiment Videos

  • Analysis of polymorphisms in metabolizing enzymes (cytochrome P450, glutathione-S-transferase), transporter proteins (reduced folate carrier, P-glycoprotein), and target proteins (thymidylate synthase, methylenetetrahydrofolate reductase, dihydrofolate reductase, c-KIT).
  • Evaluation of pharmacogenetic implications for novel agents like imatinib in gastrointestinal tumors (GIST).

    • Main Results:

    • Genetic variations in enzymes, transporters, and targets can alter clinical outcomes, including response and toxicity.
    • Specific polymorphisms may influence the effectiveness of drugs like anthracyclines and alkylating agents.
    • The genetic basis for predicting phenotypic profiles in STS and bone sarcomas remains largely undetermined.

    Conclusions:

    • Pharmacogenetic factors are critical for optimizing chemotherapy in sarcomas.
    • Further research is needed to identify reliable genetic markers for personalized sarcoma treatment.
    • Understanding genetic polymorphisms will advance the development of targeted therapies for sarcomas.